Robeco Institutional Asset Management B.V. Has $290.44 Million Holdings in Pfizer Inc. $PFE

by · The Markets Daily

Robeco Institutional Asset Management B.V. lifted its position in shares of Pfizer Inc. (NYSE:PFE – Free Report) by 12.3% during the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 11,398,565 shares of the biopharmaceutical company’s stock after purchasing an additional 1,247,082 shares during the quarter. Robeco Institutional Asset Management B.V. owned 0.20% of Pfizer worth $290,435,000 at the end of the most recent reporting period.

Other hedge funds have also bought and sold shares of the company. Fiduciary Alliance LLC raised its stake in shares of Pfizer by 46.4% in the third quarter. Fiduciary Alliance LLC now owns 145,263 shares of the biopharmaceutical company’s stock worth $3,701,000 after purchasing an additional 46,043 shares during the last quarter. Vista Investment Partners LLC grew its holdings in Pfizer by 236.1% during the third quarter. Vista Investment Partners LLC now owns 69,613 shares of the biopharmaceutical company’s stock worth $1,774,000 after buying an additional 48,900 shares in the last quarter. Westbourne Investments Inc. purchased a new stake in Pfizer in the 1st quarter valued at $2,411,000. Generali Investments CEE investicni spolecnost a.s. lifted its stake in Pfizer by 76.4% during the 3rd quarter. Generali Investments CEE investicni spolecnost a.s. now owns 109,269 shares of the biopharmaceutical company’s stock valued at $2,784,000 after acquiring an additional 47,319 shares in the last quarter. Finally, Bourne Lent Asset Management Inc. boosted its holdings in Pfizer by 90.8% during the 2nd quarter. Bourne Lent Asset Management Inc. now owns 38,255 shares of the biopharmaceutical company’s stock worth $927,000 after acquiring an additional 18,200 shares during the last quarter. Institutional investors and hedge funds own 68.36% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities research analysts have commented on PFE shares. UBS Group reiterated a “neutral” rating and issued a $28.00 price objective on shares of Pfizer in a research note on Wednesday, October 1st. Wolfe Research set a $24.00 target price on Pfizer and gave the company an “underperform” rating in a report on Wednesday, December 17th. HSBC reiterated a “buy” rating and set a $29.00 price target on shares of Pfizer in a report on Wednesday, December 10th. BMO Capital Markets restated an “outperform” rating on shares of Pfizer in a research note on Wednesday, December 10th. Finally, Wall Street Zen cut Pfizer from a “buy” rating to a “hold” rating in a research note on Sunday, September 28th. Two research analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating, thirteen have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, Pfizer has a consensus rating of “Hold” and a consensus target price of $28.06.

Read Our Latest Stock Analysis on PFE

Pfizer Stock Performance

Shares of PFE opened at $25.18 on Tuesday. Pfizer Inc. has a 1 year low of $20.92 and a 1 year high of $27.69. The company has a debt-to-equity ratio of 0.62, a current ratio of 1.28 and a quick ratio of 0.97. The stock’s fifty day moving average price is $25.19 and its two-hundred day moving average price is $24.93. The firm has a market cap of $143.14 billion, a PE ratio of 14.64 and a beta of 0.47.

Pfizer (NYSE:PFE – Get Free Report) last posted its quarterly earnings results on Tuesday, November 4th. The biopharmaceutical company reported $0.87 earnings per share for the quarter, topping the consensus estimate of $0.79 by $0.08. Pfizer had a return on equity of 20.17% and a net margin of 15.65%.The company had revenue of $16.65 billion during the quarter, compared to the consensus estimate of $16.94 billion. Pfizer has set its FY 2025 guidance at 3.000-3.150 EPS. On average, equities research analysts forecast that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, March 6th. Stockholders of record on Friday, January 23rd will be paid a $0.43 dividend. The ex-dividend date is Friday, January 23rd. This represents a $1.72 annualized dividend and a dividend yield of 6.8%. Pfizer’s dividend payout ratio (DPR) is presently 100.00%.

About Pfizer

(Free Report)

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.

Further Reading

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE – Free Report).